Anti-Amyloid Antibodies for Alzheimer’s Disease: Efficacy and Safety

Podcast: Weekly Neurology Deep Dive - A review of recent impactful publications in the field of Neurology · Amer Ghavanini

Opublikowano: 2026-09-20

This umbrella review evaluates the clinical efficacy and safety of two recently approved anti-amyloid antibodies, lecanemab and donanemab, for treating early-stage Alzheimer’s disease. By synthesizing data from eleven high-quality systematic reviews and meta-analyses, the authors conclude that these drugs successfully reduce brain amyloid burden and provide a statistically significant slowing of cognitive decline. However, the text highlights a critical concern: the observed cognitive benefits often fall below established clinically meaningful thresholds, suggesting that patients might not perceive a significant improvement in daily life. Furthermore, both treatments are associated with an increased risk of amyloid-related imaging abnormalities (ARIA), such as...